Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest

Archives of Internal Medicine

Volumn 165, Issue 6, 2005, Pages 696-701

  Liperoti, Rosa ^a   Gambassi, Giovanni ^a,b   Lapane, Kate L ^b   Chiang, Claire ^b   Pedone, Claudio ^a   Mor, Vincent ^b   Bernabei, Roberta ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; CORTICOSTEROID; FLUPHENAZINE; HALOPERIDOL; INOTROPIC AGENT; LOOP DIURETIC AGENT; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; POTASSIUM SPARING DIURETIC AGENT; PROMAZINE; QUETIAPINE; RISPERIDONE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; VASODILATOR AGENT;

AGED; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; NURSING HOME; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ARRHYTHMIA; CASE-CONTROL STUDIES; FEMALE; HEART ARREST; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; NURSING HOMES; PSYCHOTIC DISORDERS; RISK FACTORS; UNITED STATES;

EID: 15344349986     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.6.696     Document Type: Article

References (43)

1. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164:1293-1297.
2. Shader RI, Greenblatt DJ. Potassium, antipsychotic agents, arrhythmias, and sudden death. J Clin Psychopharmacol. 1998;18:427-428.
3. Giles TD, Modlin RK. Death associated with ventricular arrhythmia and thioridazine hydrochloride. JAMA. 1968;205:108-110.
4. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med. 1997;157:2013-2015.
5. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand. 2003;107: 85-95.
6. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325:1070-1074.
7. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161-1197.
8. Studenik C, Lemmens-Gruber R, Heistracher P. Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur J Pharm Sci. 1999;7:113-118.
9. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048-1052.
10. Kapur S, Remington G. Atypical antipsychotics. BMJ. 2000;321:1360-1361.
11. American Geriatrics Society and American Association for Geriatric Psychiatry. Consensus statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc. 2003;51:1287-1298.
12. Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv. 2002;53:425-430.
13. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64:1106-1112.
14. Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol. 2000; 20:325-327.
15. Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother. 1997;31:867-870.
16. Bernabei R, Gambassi G, Lapane KL, et al. Characteristics of the SAGE data-base: a new resource for research on outcomes in long-term care: SAGE (Systematic Assessment of Geriatric drug use via Epidemiology) Study Group. J Gerontol A Biol Sci Med Sci. 1999;54:M25-M33.
17. Gambassi G, Landi F, Peng L, et al. Validity of diagnostic and drug data in standardized nursing home assessments: potential for geriatric pharmacoepidemiology. Med Care. 1998;36:167-179.
18. Gambassi G, Lapane KL, Sgadari A, et al. Effects of angiotensin- converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. Arch Intern Med. 2000;160:53-60.
19. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
20. Intrator O, Castle NG, Mor V. Facility characteristics associated with hospitalization of nursing home residents: results of a national study. Med Care. 1999; 37:228-237.
21. Katz S, Moskowitz RW, Jackson BA, Jafee MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914-919.
22. Morris JN, Fries BE, Mehr DR, et al. MDS cognitive performance scale. J Gerontol. 1994;49:M174-M182.
23. Gambassi G, Lapane KL, Sgadari A, Landi F, Mor V, Bernabei R. Measuring health outcomes for older people using the SAGE database. Can J Aging. 2000;19 (suppl 2):67-86.
24. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51:1305-1317.
25. Rothman KJ, Greenland S. Concepts of interaction. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998:329-342.
26. Classman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry. 2001;158:1774-1778.
27. Kang UG, Kwon JS, Ahn YM, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry. 2000;61:441-446.
28. Bosch RF, Baumbach A, Bitzer M, Erley CM. Intoxication with olanzapine. Am J Psychiatry. 2000;157:304-305.
29. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG; Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997;54:549-557.
30. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-418.
31. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-774.
32. Moore NC, Shukla P. Risperidone overdose. Am J Psychiatry. 1997;154:289-290.
33. Kopala LC, Day C, Dillman B, Gardner D. A case of risperidone overdose in early schizophrenia: a review of potential complications. J Psychiatry Neurosci. 1998; 23:305-308.
34. Capel MM, Clobridge MG, Henry JA. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol. 2000;3:51-54.
35. Hägg S, Spigsest O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs. 2002;16:765-776.
36. Committee on Safety of Medicines. Latest news: March 9, 2004: Atypical antipsychotic drugs and stroke. Available at: http://www.mca.gov.uk/aboutagency /regframework/csm/csmhome.htm. Accessed April 28, 2004.
37. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy. 2003;23:881-908.
38. Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289;2120-2127.
39. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28(suppl 1):83-96.
40. Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol. 2001; 21:8-13.
41. Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ. 2001;322:1207-1209.
42. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329:75.
43. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64:701-723.